Can you get medical cannabis for chronic pain in the UK?
Chronic non-cancer pain — long-term back pain, neck pain, widespread musculoskeletal pain — is the single most common reason people are prescribed medical cannabis privately in the UK. It is also the condition where NICE has looked at the evidence and recommended against it. Holding both facts together is the honest starting point.
The short answer
- It is not a qualifying condition. The UK has no such list; the decision belongs to a specialist.
- NICE recommends against cannabis-based medicines for chronic pain outside a clinical trial (NG144).
- Private specialists still prescribe for it, as an unlicensed medicine for individuals whose standard treatments have failed.
- Expect a monitored trial, with a review point and a plan to stop if it does not help.
- The evidence is weak and contested, which is exactly why your clinician should be candid about uncertainty.
Is chronic pain treated with medical cannabis in the UK?
Yes, in private practice, and more often than any other condition. No, as a routine NHS treatment — no cannabis-based medicine is licensed for chronic non-cancer pain in the UK, and NICE guideline NG144 recommends against offering one outside a clinical trial.
The gap between those two sentences is the whole story. NICE assessed whether the NHS should offer these medicines to a population of chronic pain patients and concluded the evidence did not support it. That guidance does not remove a specialist's legal ability to prescribe an unlicensed medicine to an individual with unmet clinical need. Private prescribing occupies that space, and the honest framing for it is a supervised trial in someone who has run out of better options — not an established treatment.
In practice this covers long-term back and neck pain, widespread musculoskeletal pain, post-surgical pain that never settled, and pain that no longer has a clear structural explanation. If your pain is specifically nerve pain, see neuropathic pain, where the evidence has been studied separately.
What the evidence actually shows
Randomised trial evidence in chronic non-cancer pain is thin, mostly short, and mostly small. The larger body of UK data is observational — real-world outcomes from patients already being treated, which cannot separate the medicine from expectation, natural fluctuation, or the effect of finally being taken seriously.
The UK Medical Cannabis Registry, run through a UK clinic and analysed by researchers at Imperial College London, has published outcomes for chronic pain patients showing improvements in pain-specific scores and health-related quality of life, with mostly mild-to-moderate side effects. The authors are explicit that causation cannot be inferred from this kind of study, and that randomised trials are still needed. That is the state of the field: encouraging signals, no proof.
Read alongside it the NICE conclusion, which is drawn from the same literature and reaches a different conclusion because it is answering a different question. We unpack that tension in Can medical cannabis treat my condition?
The study behind that paragraph
Pillai M, Erridge S, Bapir L, et al. UK Medical Cannabis registry: an analysis of clinical outcomes of medicinal cannabis therapy for chronic pain conditions. Expert Review of Clinical Pharmacology. 2022;15(4):473-484. A prospective UK cohort study reporting improvements in pain-specific and quality-of-life measures, with the authors noting that causation cannot be inferred from observational data.
What a specialist will want to see
There is no UK list of qualifying conditions, so nothing here entitles you to a prescription. A specialist works through your history and decides whether a monitored trial is justified for you. For chronic pain they will typically look at:
- How long the pain has lasted, where it is, and whether there is a diagnosis behind it
- Which standard treatments you have tried — typically at least two — and why each was stopped or judged inadequate
- Whether you are on opioids, gabapentinoids, antidepressants or benzodiazepines, and at what doses
- What you actually want to change: pain scores, sleep, function, or reducing another medicine
- Your personal and family history of psychosis, and your current mental health
- Whether you drive, and whether you work in a safety-critical role
The general requirements — age, a documented diagnosis, the convention that two standard treatments have been tried, and access to your medical records — are covered in What are the requirements?
Risks and reasons a specialist may say no
The common side effects are dizziness, drowsiness, dry mouth, appetite changes and difficulty concentrating. THC-containing products can impair driving, and it is an offence to drive while impaired even with a valid prescription.
A specialist is likely to decline, or to proceed only with a very cautious plan, if you have a personal or family history of psychosis or schizophrenia, an unstable serious mental illness, significant cardiovascular disease, or if you are pregnant or breastfeeding. High-dose opioid use alongside cannabis-based medicines needs care rather than an automatic no.
Chronic pain is also the condition where expectations most often outrun what the medicine can do. A realistic target is a modest improvement in pain and function that makes the side effects worth it — not the disappearance of pain.
If you want to take this further
The useful next step is a proper assessment, not a better list. Gather your diagnosis, the treatments you have already tried and what happened with each, and your current medicines — that is what a specialist needs in order to give you a straight answer.
The consultation itself, and what happens after it, is set out in What is the process to get a medical cannabis prescription? If chronic pain is not the only thing you are being treated for, say so early: other conditions and other medicines change the assessment.
Frequently asked questions
Can I get medical cannabis for chronic pain in the UK?
You can be assessed for it privately, and chronic pain is the most common reason for private prescriptions in the UK. It is not a qualifying condition in any legal sense, and NICE guideline NG144 recommends against cannabis-based medicines for chronic pain outside a clinical trial. A specialist may still prescribe for an individual whose standard treatments have failed, framed as a monitored trial.
Will the NHS prescribe medical cannabis for chronic pain?
Almost never. No cannabis-based product is licensed in the UK for chronic non-cancer pain, and NICE recommends against offering one outside a clinical trial. NHS prescribing is concentrated on the three licensed uses: severe childhood epilepsies, MS spasticity and chemotherapy-induced sickness.
Does medical cannabis work for back pain?
The trial evidence for long-term back pain specifically is limited and of low quality. UK real-world registry data reports improvements in pain and quality of life for chronic pain patients generally, but observational data cannot show cause and effect. A specialist should describe treatment as a trial with a review point rather than predict a result.
Can I stay on my opioids if I am prescribed medical cannabis?
That is a clinical decision for your prescriber, made with your GP where shared care applies. Being on opioids does not rule you out, but it changes the assessment, and any reduction should be planned and supervised rather than attempted on your own.
Sources and further reading
Every factual statement on this page is drawn from the following public sources. Links open in a new tab and are not affiliated with Flora House.
- Pillai M, et al. UK Medical Cannabis registry: an analysis of clinical outcomes of medicinal cannabis therapy for chronic pain conditions. Expert Review of Clinical Pharmacology (2022)
- NICE NG144: Recommendations
- NHS: How to get NHS help for your pain
- NICE guideline NG144: Cannabis-based medicinal products
- NHS: Medical cannabis (and cannabis oils)
- House of Commons Library briefing CBP-8355: Medical use of cannabis
- MHRA: The supply, manufacture, importation and distribution of unlicensed cannabis-based products for medicinal use